Hepatocellular carcinoma, or HCC, is the most common primary cancer arising in the liver. When tumors cannot be surgically removed, treatment becomes substantially more difficult because the disease may involve major blood vessels, occupy large portions of the liver or have spread beyond the organ. One approach is transarterial chemoembolization, known as TACE, in which physicians guide a catheter through the blood vessels to arteries feeding a tumor. Chemotherapy is delivered locally, while embolic material blocks the tumor’s blood supply. The procedure can expose cancer cells to high drug concentrations and deprive them of oxygen, but it does not always eliminate all malignant tissue.

The other components of the combination attack the disease through different biological pathways. Lenvatinib is a tyrosine kinase inhibitor that blocks signaling proteins involved in blood-vessel formation and tumor growth. HCC tumors often stimulate the development of new vessels to secure oxygen and nutrients; inhibiting pathways involving vascular endothelial growth factor receptors can restrict that support. PD-1 inhibitors work through the immune system. PD-1 is a checkpoint protein on immune cells that can be exploited by tumors to suppress T-cell activity. Blocking the PD-1 pathway may restore part of the immune response against cancer. In principle, TACE can release tumor antigens and alter the tumor environment, lenvatinib can restrain angiogenesis, and immunotherapy can mobilize immune cells against remaining cancer cells.

Although this three-part treatment, abbreviated T-L-P by the researchers, has shown encouraging activity, its effects vary considerably from one patient to another. Some patients experience substantial tumor shrinkage and prolonged disease control, while others progress despite treatment. Clinicians therefore need practical ways to identify likely responders and recognize patients whose disease or underlying liver dysfunction may limit the benefit. The research team, led by Pengpeng Zhu and Kaile Tian, examined medical records from patients who began T-L-P therapy between 2020 and 2022. The investigators randomly or administratively divided the study population into a training cohort of 90 patients, used to develop the model, and a validation cohort of 64 patients, used to test whether it retained its predictive value.

The researchers first assessed objective response rate, or ORR, which measures the proportion of patients whose tumors met predefined criteria for complete or partial shrinkage. They also examined disease control rate, which includes responses as well as stable disease. In the training cohort, 44 of 90 patients, or 48.9 percent, achieved an objective response, while 72 patients, or 80 percent, achieved disease control. In the validation cohort, the corresponding figures were 38 of 64 patients, or 59.4 percent, for objective response and 52 patients, or 81.3 percent, for disease control. These results describe outcomes in the selected study population and should not be interpreted as proof that the treatment will produce the same response rates in every clinical setting.

Statistical analysis identified three independent factors associated with objective response. The first was an alpha-fetoprotein concentration above 100 nanograms per milliliter. AFP is a protein produced during fetal development that can reappear at high levels in some people with HCC, although it is neither present in every case nor specific to this cancer. The second factor was a tumor burden score above 8. TBS combines tumor size and number into a single measure, generally increasing as tumors become larger or more numerous. The third was Child-Pugh class B liver function, a category indicating more substantial impairment than class A. The Child-Pugh system incorporates measures such as bilirubin, albumin, blood clotting, fluid accumulation and encephalopathy to estimate the liver’s functional reserve.

Each of these features was assigned one point in the ATC score, producing a range from zero to three. The name reflects the principal variables used in the model: AFP, tumor burden and Child-Pugh classification. Patients with no risk factors had a score of zero and were designated low risk; those with one factor had an intermediate-risk score of one; and those with two or three factors were placed in the high-risk group. The score is not a molecular test and does not directly measure immune activity, drug concentration or genetic mutations. Instead, it combines readily available indicators of tumor biology and the liver’s ability to withstand both cancer and treatment.

The differences between the groups were striking. In the training cohort, the estimated two-year overall survival rate was 83.57 percent for patients with an ATC score of zero, 64.13 percent for those scoring one and 20.69 percent for those scoring at least two. Two-year progression-free survival, which measures the length of time before the cancer worsens or the patient dies, was 66.48 percent, 46.55 percent and 9.33 percent in the same groups. The validation cohort showed a similar pattern: two-year overall survival was 94.12 percent for score zero, 64.71 percent for score one and 25.93 percent for scores of two or three. Two-year progression-free survival was 82.35 percent, 47.06 percent and 16.67 percent, respectively.

To evaluate discrimination, the investigators used the area under the receiver operating characteristic curve, or AUC. This statistic summarizes how well a model distinguishes between patients who do and do not experience an outcome, with a value of 0.5 representing chance performance and values closer to 1 indicating stronger discrimination. The ATC score achieved an AUC of 0.826 in the training cohort and 0.811 in the validation cohort. According to the study, this performance was better than that of any individual component alone. The validation result is particularly important because a model can appear highly accurate in the same data used to build it but lose performance in a separate group.

The researchers say the score could support treatment planning by providing an early estimate of expected benefit from T-L-P therapy. A patient with a low score might be considered a strong candidate for continuing an intensive combination approach, assuming treatment is otherwise safe and appropriate. A high score could prompt closer monitoring, more detailed discussion of alternatives or consideration of clinical trials designed for patients with difficult-to-treat disease. The model might also help researchers balance participants across risk categories in future studies, making it easier to determine whether a new therapy helps patients with poor baseline prognoses rather than simply reflecting differences between trial populations.

The results nevertheless come with important limitations. The study was retrospective, meaning the investigators analyzed existing records rather than assigning treatment prospectively under a controlled protocol. All 154 patients received the same general treatment combination, but unmeasured differences in disease characteristics, supportive care or clinical decision-making could have influenced the outcomes. The sample was also relatively small and drawn from institutions in China, so the model requires testing in larger, geographically diverse populations before it can be considered broadly reliable. In addition, a score that predicts response at the group level cannot determine an individual patient’s fate. Some people with high scores may respond exceptionally well, while some with low scores may not benefit.

The findings add to a growing effort to make combination therapy for advanced liver cancer more precise. TACE, targeted therapy and immune checkpoint blockade each affect a different part of the tumor ecosystem, but the same complexity that creates therapeutic potential also makes outcomes difficult to anticipate. The ATC score offers a deliberately simple framework built from clinical information already collected in routine care. Its next test will be prospective validation: researchers will need to apply the score before treatment begins, follow patients under standardized conditions and determine whether it improves decisions rather than merely describing prognosis. Until then, the model is best viewed as a promising research tool—one that could help clinicians move closer to matching the right treatment intensity to the biology of an individual patient.

Recurrent HCC poses a significant clinical challenge due to its frequent resistance to conventional therapies and the complex hepatic environment in which tumors often develop. SBRT has emerged as an innovative local treatment modality by delivering high doses of focused radiation to tumor sites with precision, thereby sparing surrounding healthy liver tissue. Meanwhile, TACE remains a cornerstone in managing liver cancer, functioning through catheter-based delivery of chemotherapeutic agents paired with embolic materials to induce ischemic tumor necrosis.

The novelty of this investigation lies in the sequential application of TACE following SBRT, a treatment protocol that aims to leverage the complementary mechanisms of radiation-induced tumor damage and chemoembolization-induced ischemic cytotoxicity. Until now, limited comparative data existed to convincingly assess whether this sequential combination confers survival advantages without imposing additional toxicity burdens on patients.

The researchers retrospectively reviewed 152 patients with recurrent HCC, subdividing them into two cohorts: 109 patients treated with SBRT alone and 43 patients receiving the combination of SBRT followed by TACE. To reduce confounding variables and selection bias, propensity score matching was employed, yielding 68 patients in the SBRT-alone group and 36 patients in the SBRT plus TACE group for robust comparative analyses.

Outcomes such as overall survival (OS), progression-free survival (PFS), and local control were analyzed through Kaplan-Meier survival methods. Notably, the combination therapy group exhibited numerically higher survival rates across multiple time points. The one-, three-, and five-year OS rates in the SBRT-alone group were 91.2%, 76.3%, and 61.8% respectively, compared to 100.0%, 86.1%, and 77.5% in the combined therapy group. Progression-free survival similarly trended higher in patients receiving the sequential treatment.

Despite these encouraging trends, the differences between groups did not attain statistical significance, with p-values of 0.069 for overall survival and 0.091 for progression-free survival. Nevertheless, this signals a potentially meaningful clinical benefit that warrants further validation. Importantly, the safety assessment revealed no occurrence of acute grade 3 or higher toxicities in either group, affirming that the addition of TACE to SBRT does not exacerbate treatment-related adverse events.

The underlying biological rationale for combining SBRT with TACE is multifaceted. Radiation therapy may enhance tumor oxygenation and permeability temporarily, facilitating better delivery and retention of chemotherapeutic agents during subsequent TACE. Additionally, SBRT-induced tumor necrosis can sensitize residual cancer cells to ischemic insult, thus potentially amplifying the cytotoxic effects of chemoembolization.

Moreover, SBRT’s precise radiation targeting limits damage to adjacent hepatic parenchyma, which is critical in patients with compromised liver function frequently encountered in recurrent HCC. Integrating TACE post-radiation might further consolidate local tumor control by eradicating microscopic residual disease and inhibiting tumor angiogenesis, thereby reducing recurrence risk.

This exploratory study’s findings contribute valuable clinical insights by establishing a safety profile for the sequential approach and generating initial efficacy signals. However, the authors emphasize the necessity of larger-scale, prospective randomized controlled trials to definitively ascertain whether combining SBRT with TACE improves long-term survival and quality of life outcomes in recurrent HCC patients.

Implementing combination locoregional therapies also requires careful patient selection and multidisciplinary collaboration, balancing therapeutic intensification with preservation of liver function. Optimization of treatment sequencing, dosing parameters, and interval timing between SBRT and TACE warrants further investigation to maximize synergistic effects while minimizing complications.

In the context of evolving systemic therapies and immunotherapeutic agents under development for liver cancer, integrating local modalities like SBRT and TACE into multimodal regimens may unlock new therapeutic frontiers. Understanding the molecular and immunological tumor microenvironment alterations induced by these treatments could pave the way for personalized strategies that harness immune responses alongside direct cytotoxicity.

As the global burden of HCC continues to rise, innovative approaches addressing recurrent disease are urgently needed. This study’s demonstration of favorable trends without increased toxicity highlights a promising avenue in the pursuit of improved survival outcomes for patients facing limited options after initial treatments fail.

In summary, the sequential administration of transarterial chemoembolization after stereotactic body radiation therapy offers a potentially effective and safe treatment strategy for recurrent hepatocellular carcinoma. While definitive conclusions await more extensive trials, these preliminary results provide a compelling foundation for future research aimed at refining liver cancer therapeutics and ultimately enhancing patient prognosis.

Subject of Research:
The comparative efficacy of sequential transarterial chemoembolization following stereotactic body radiation therapy versus radiation therapy alone in recurrent hepatocellular carcinoma.

Article Title:
Efficacy of Sequential Transarterial Chemoembolization after Stereotactic Body Radiation Therapy versus Radiation Therapy Alone for Recurrent Hepatocellular Carcinoma: A Propensity Score-matched Analysis

News Publication Date:
13 March 2026

Web References:
https://www.xiahepublishing.com/journal/jcth
http://dx.doi.org/10.14218/JCTH.2025.00568

Image Credits:
Wen-Gang Li, Xue-Zhang Duan

Keywords:
Hepatocellular carcinoma, recurrent liver cancer, stereotactic body radiation therapy, transarterial chemoembolization, combination therapy, survival analysis, locoregional treatment, liver oncology, cancer therapy innovations

The incidence of hepatocellular carcinoma, particularly among individuals aged 70 and above, poses significant clinical challenges due to comorbidities and the reduced physiological resilience of this population. Standard therapeutic approaches, such as TACE, though widely used, often manifest considerable adverse effects with suboptimal long-term outcomes in elderly patients. Against this backdrop, the present retrospective analysis leverages clinical data from 82 elderly uHCC patients treated at Wuhan Union Hospital between 2019 and 2022, stratified into two cohorts receiving either HAIC combined with lenvatinib or TACE monotherapy.

Dissecting the molecular underpinnings of this combined regimen reveals a synergistic mechanism where raltitrexed, a thymidylate synthase inhibitor, and oxaliplatin, a platinum-based chemotherapeutic agent, deliver potent cytotoxicity directly to the hepatic tumor via arterial infusion. Concurrently, lenvatinib’s antiangiogenic properties disrupt tumor vasculature and inhibit key signaling pathways essential for tumor growth and proliferation, thereby augmenting the cytotoxic impact of HAIC.

Quantitative outcomes from the study underscore the superiority of the HAIC plus lenvatinib combination. The objective response rate (ORR), a critical measure of tumor shrinkage post-therapy, was significantly higher at 61.5% in the combination group versus 37.2% in patients undergoing TACE. Similarly, the disease control rate (DCR), encompassing both tumor response and stabilization, improved dramatically to 82.1% compared to 58.1% in the control group, suggesting enhanced disease management efficacy.

Crucially, survival metrics emphasize the real-world benefit of this novel therapeutic strategy. Median progression-free survival (mPFS)—the interval during which patients show no disease progression—was extended to 9.2 months for those receiving RALOX-HAIC plus lenvatinib, more than doubling the 4.6 months observed in the TACE cohort. Even more striking was the prolongation of overall survival (OS), with the experimental group achieving a median of 18.1 months compared to just 10.6 months in the TACE group, indicating a nearly 70% improvement.

Safety and tolerability analyses further delineate the clinical advantage of the combination regimen, revealing substantially fewer incidences of abdominal pain and fever relative to TACE-treated patients. While hand-foot syndrome, a recognized adverse effect associated with lenvatinib, was more frequent in the combination group (15.4% versus none in TACE), the severity did not escalate into critical toxicity, with grade 3 or 4 cases remaining rare and statistically insignificant.

The study’s retrospective design, though limiting causal inferences, provides robust real-world evidence supporting the integration of systemic targeted therapy with localized chemotherapy infusion for challenging hepatocellular carcinoma cases in an elderly demographic. Importantly, this combined approach opens avenues for tailored oncological care that balances efficacy with quality of life considerations for a vulnerable patient subset.

At a cellular level, the therapeutic approach exploits the hepatic artery’s favorable pharmacokinetics for delivering high-dose chemotherapeutic agents directly to tumor sites, reducing systemic exposure and minimizing collateral damage to healthy tissues. Raltitrexed’s action inhibits DNA synthesis, while oxaliplatin induces DNA cross-links, together crippling cancer cell replication. Lenvatinib’s inhibition of VEGFR, FGFR, and PDGFR pathways simultaneously halts angiogenesis, cutting off the tumor’s blood supply essential for its sustenance.

This multi-modal assault disrupts tumor microenvironment homeostasis, impeding progression and metastatic potential, which is paramount in advanced unresectable cases where surgical options are precluded. Moreover, the favorable safety profile observed indicates that elderly patients tolerate the combination well, an aspect crucial for adherence and sustained therapeutic success in geriatric oncology.

The implications of this study herald a paradigm shift in managing elderly patients with uHCC, traditionally a cohort fraught with therapeutic dilemmas due to frailty and comorbid disease burdens. By leveraging a carefully calibrated combination of local and systemic agents, clinicians can now envisage improved survival outcomes without compromising patient safety, thereby addressing a critical unmet need in hepatic oncology.

Furthermore, the findings suggest potential applicability beyond elderly populations, warranting exploration in younger cohorts and in diverse clinical settings. The interplay between HAIC-induced cytotoxicity and lenvatinib’s molecular targeting invites translational research to optimize dosing regimens, sequencing, and combination partners to enhance therapeutic indices.

In addition to efficacy and safety, patient-centric aspects such as treatment convenience, hospitalization time, and quality of life parameters merit future prospective studies. The retrospective data from the Wuhan Union Hospital cohort provide a compelling foundation upon which randomized controlled trials can be designed to validate these promising results.

This therapeutic strategy also aligns with precision medicine trends, where molecular profiling and tumor biology insights inform individualized treatment plans. As hepatocellular carcinoma often harbors heterogeneous genetic alterations, combinatorial regimens like RALOX-HAIC plus lenvatinib may prove effective in overcoming resistance mechanisms inherent in monotherapies.

Moreover, the integration of real-world clinical data underscores the importance of observational studies in generating actionable knowledge, particularly when rapid translation to practice is critical for patient outcomes. The comprehensive analysis of adverse events alongside survival data strengthens the clinical relevance of the findings.

In conclusion, the study pioneers a compelling therapeutic avenue that combines the local high-dose chemotherapy benefits of RALOX-HAIC with the systemic inhibitory effects of lenvatinib to substantially improve treatment responses and survival in elderly uHCC patients. This advancement marks a significant stride toward more effective, safer, and patient-tailored management of unresectable hepatocellular carcinoma, promising a beacon of hope for a patient population in dire need of optimized cancer care.

Subject of Research: Efficacy and safety of RALOX-HAIC combined with lenvatinib in elderly patients with unresectable hepatocellular carcinoma

Article Title: RALOX-HAIC (raltitrexed + oxaliplatin) combined with lenvatinib improves survival and safety in elderly patients with unresectable hepatocellular carcinoma

Article References:
Lu, H., Gao, Y., Xia, X. et al. RALOX-HAIC (raltitrexed + oxaliplatin) combined with lenvatinib improves survival and safety in elderly patients with unresectable hepatocellular carcinoma. BMC Cancer 25, 882 (2025). https://doi.org/10.1186/s12885-025-14274-x

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14274-x

Hepatocellular carcinoma remains one of the most prevalent malignancies worldwide and carries a notoriously high recurrence rate following surgical resection. Such recurrences often present as unresectable lesions, demanding alternative therapeutic approaches. Despite advances in loco-regional therapies, no standardized treatment regimen currently exists for managing recurrent unresectable HCC, highlighting an urgent unmet clinical need.

The study, published in BMC Cancer, retrospectively analyzed clinical data from 83 patients diagnosed with recurrent unresectable HCC after initial surgery. The patients were stratified into three distinct treatment cohorts based on their regimens: a group receiving HAIC combined with TKIs and PD-1 inhibitors (HTP), a second group treated with TACE in combination with TKIs and PD-1 inhibitors (TTP), and a third control group undergoing TACE alone. This design enabled a robust comparative assessment of treatment efficacy and safety among cutting-edge combination therapies versus standard intervention.

HAIC and TACE are both hepatic artery-targeted therapies aimed at delivering chemotherapeutic agents directly to liver tumors, thereby maximizing local antitumor activity while limiting systemic toxicity. Combining these modalities with TKIs, which inhibit angiogenesis and tumor proliferation pathways, alongside PD-1 inhibitors that unleash anti-tumor immune responses, represents an innovative multimodal approach to tackle tumor progression on multiple fronts simultaneously.

The primary endpoint assessed was progression-free survival (PFS), a critical measure reflecting the duration during which patients remained free from disease advancement. Results revealed a marked improvement in median PFS among patients receiving combination therapy. Specifically, the HTP group demonstrated a median PFS of 13.7 months, substantially longer than the 9.2 months observed in the TTP group and dramatically exceeding the 2.5 months recorded for those treated with TACE alone. These findings underscore the additive benefit of incorporating both TKIs and PD-1 inhibitors alongside hepatic arterial infusion strategies.

Beyond survival metrics, tumor response was meticulously evaluated using modified Response Evaluation Criteria in Solid Tumors (mRECIST), a standard for assessing therapeutic efficacy in HCC that accounts for changes in viable tumor tissue. The disease control rate (DCR), encompassing complete response (CR), partial response, and stable disease, was significantly higher in the HTP cohort at 89.7%, compared to 75.0% in the TTP group and only 50.0% with TACE monotherapy. The objective response rate (ORR), indicative of measurable tumor shrinkage, also favored combination regimens, reaching 44.8% and 35% in the HTP and TTP groups respectively, versus a mere 14.7% in the control group.

Remarkably, the incidence of complete response was restricted to the HTP group, with 17.2% of patients achieving this outcome. This contrasts starkly with a complete response rate of zero in both the TTP and TACE alone arms. Such results suggest that HAIC, when synergized with TKIs and PD-1 checkpoint blockade, may elicit profound antitumor effects potentially capable of eradicating clinically evident disease in a subset of patients.

Safety profiles across treatment arms were carefully monitored, revealing no occurrences of serious adverse reactions within the HTP and TTP groups. This highlights the tolerability of these combination regimens, which is pivotal considering the typically compromised hepatic reserve and overall frailty of advanced HCC patients. The absence of severe toxicity supports the feasibility of integrating immunotherapy and targeted agents with locoregional chemotherapy in clinical practice.

Mechanistically, the therapeutic synergy observed likely stems from complementary modes of action. TKIs suppress tumor angiogenesis and cellular proliferation, thereby restricting nutrient supply and direct tumor growth. PD-1 inhibitors enhance the host immune system’s capacity to recognize and destroy cancer cells by preventing immune checkpoint-mediated T cell exhaustion. Concurrently, HAIC and TACE deliver localized cytotoxic chemotherapy that induces tumor necrosis. This concerted attack disrupts the tumor microenvironment, potentially overcoming resistance mechanisms seen with monotherapy.

This study’s implications extend far beyond survival statistics. It emphasizes the evolving landscape of HCC treatment, where integrating systemic immunomodulation and targeted therapy with traditional intra-arterial chemotherapy heralds a new era of personalized oncology. Identifying patients most likely to benefit from such regimens remains an ongoing challenge, necessitating further biomarker-driven investigations.

Despite its retrospective design and relatively modest sample size, the research offers compelling evidence warranting prospective, randomized clinical trials to validate these findings. The ability to induce complete responses in previously refractory recurrent HCC patients could translate into durable remissions and improved overall survival, transforming standard care paradigms.

In summary, the combination of TKIs and PD-1 inhibitors with HAIC or TACE demonstrates superior efficacy and safety compared to TACE alone in treating recurrent unresectable hepatocellular carcinoma. Particularly, HAIC combined with these systemic agents achieves the highest complete response rates, shedding light on promising therapeutic avenues. As liver cancer continues to pose formidable clinical challenges, these findings pave the way toward more effective, multimodal treatment strategies that improve patient outcomes and quality of life.

Future research should aim to elucidate the molecular underpinnings driving response heterogeneity and resistance, optimize dosing schedules, and evaluate long-term survivorship benefits. Moreover, integrating advanced imaging modalities and liquid biopsy approaches may facilitate early detection of treatment response and recurrence, further refining clinical decision-making. Ultimately, multidisciplinary collaboration will be key to translating these scientific insights into routine clinical application.

The study stands as a testament to the rapidly advancing frontier of oncological therapeutics, underscoring the power of combining precision medicine, immunotherapy, and locoregional interventions. As these innovations converge, they offer renewed optimism for patients confronting the formidable challenge of recurrent unresectable hepatocellular carcinoma.

Subject of Research: Treatment efficacy and safety of tyrosine kinase inhibitors and programmed cell death protein-1 inhibitors combined with hepatic arterial infusion chemotherapy/transarterial chemoembolization for recurrent unresectable hepatocellular carcinoma.

Article Title: The safety and efficacy of tyrosine kinase inhibitors and programmed cell death protein-1 inhibitors combined with HAIC/TACE in the treatment of recurrent unresectable hepatocellular carcinoma.

Article References:
Deng, W., Xie, J., Wang, T. et al. The safety and efficacy of tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors combined with HAIC/TACE in the treatment of recurrent unresectable hepatocellular carcinoma. BMC Cancer 25, 779 (2025). https://doi.org/10.1186/s12885-025-14185-x

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14185-x